These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8005974)

  • 1. Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
    Seshiah V; Venkataraman S; Suresh K
    J Assoc Physicians India; 1993 Jun; 41(6):367-8. PubMed ID: 8005974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes.
    Sinha A; Formica C; Tsalamandris C; Panagiotopoulos S; Hendrich E; DeLuise M; Seeman E; Jerums G
    Diabet Med; 1996 Jan; 13(1):40-6. PubMed ID: 8741811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of gliclazide in the treatment of non-insulin-dependent diabetes mellitus: a Canadian multicenter study.
    Mailhot J
    Clin Ther; 1993; 15(6):1060-8. PubMed ID: 8111803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added benfluorex in obese insulin-requiring type 2 diabetes.
    Leutenegger M; Bauduceau B; Brun JM; Guillon-Metz F; Martin C; Nicolino-Peltier C; Richard JL; Vannereau D
    Diabetes Metab; 1998 Feb; 24(1):55-61. PubMed ID: 9534010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliclazide in the treatment of obese NIDDM patients.
    Kumar S; Keswani P; Bose BS; Agrawal JK
    J Assoc Physicians India; 1994 Feb; 42(2):176-7. PubMed ID: 7646644
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
    Guillausseau PJ; Greb W
    Diabetes Metab; 2001 Apr; 27(2 Pt 1):133-7. PubMed ID: 11353879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
    Habib SS; Aslam M; Naveed AK; Razi MS
    Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease.
    Pontiroli AE; Calderara A; Pacchioni M; Cassisa C; Pozza G
    Diabete Metab; 1993; 19(1):30-5. PubMed ID: 8504882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
    Golay A; Broquet C; Chabot V; Studer S; Felber JP
    Schweiz Med Wochenschr; 1984 Feb; 114(8):261-4. PubMed ID: 6369531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
    Zargar AH; Siraj M; Jawa AA; Hasan M; Mahtab H
    Int J Clin Pract; 2010 Jul; 64(8):1090-4. PubMed ID: 20455956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)].
    Palel G; Coman A; Petrovanu R; Ungureanu D; Cojocaru M
    Rev Med Chir Soc Med Nat Iasi; 1997; 101(3-4):120-2. PubMed ID: 10756782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus.
    Chen KW; Juang JH; Huang HS; Lin JD; Huang BY; Huang MJ
    Changgeng Yi Xue Za Zhi; 1993 Dec; 16(4):246-50. PubMed ID: 8313208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of rigid dietary restrictions on the control of blood sugar in obese type II diabetic patients].
    La Nave G; Capani F; Consoli A; Sensi S
    Boll Soc Ital Biol Sper; 1984 Dec; 60(12):2267-71. PubMed ID: 6529503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term improvement in insulin response with gliclazide treatment.
    Bodansky HJ; Medback S; Cudworth AG; Rees LH; de Silva RS
    Diabete Metab; 1982 Dec; 8(4):319-22. PubMed ID: 6761187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.